Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Bamlanivimab vs placebo Development of clinical COVID‐19 symptoms within 30 days · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Admission to hospital within 30 days · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Adverse events: grade 3 to 4 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Outcomes · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Tixagevimab/cilgavimab vs placebo Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Tixagevimab/cilgavimab vs placebo Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Tixagevimab/cilgavimab vs placebo Adverse events: grade 3 to 4 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone All‐cause mortality up to 120 days ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Clinical improvement: discharged alive ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Clinical worsening: new need for invasive mechanical ventilation or death ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Serious adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Hospital‐acquired infections ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Invasive fungal infections ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg) Clinical worsening: new need for invasive mechanical ventilation or death ‐ not reported · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Improvement of clinical status: time to symptom resolution · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§ Ivermectin for preventing and treating COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR QoL at longest · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings… Ivermectin for preventing and treating COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Large‐volume residual disease (LVRD) > 1 cm vs no macroscopic residual disease (NMRD) Progression‐free survival · women with advanced EOC after primary IDS Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian… (2022) · Cochrane | no estimate extracted | NR | No studies |
Steroids vs cyclosporine A Adverse effect: new cataract formation · people with dry eye Topical corticosteroids for dry eye (2022) · Cochrane | no estimate extracted | NR | No studies |
Steroids vs lubricants Change in patient‐reported quality of life scores · people with dry eye Topical corticosteroids for dry eye (2022) · Cochrane | no estimate extracted | NR | No studies |
Steroids vs cyclosporine A Change in patient‐reported quality of life scores · people with dry eye Topical corticosteroids for dry eye (2022) · Cochrane | no estimate extracted | NR | No studies |
Mask vs prongs Neurodevelopmental impairment · preterm infants receiving nasal CPAP Masks versus prongs as interfaces for nasal continuous positive airway pressure in preterm infants (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ LSSS intervention vs regular salt Hypertension ‐ not measured · children (2 to < 18 years) in the general population Replacing salt with low‐sodium salt substitutes (LSSS) for cardiovascular health in adults, children and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ LSSS intervention vs regular salt Blood pressure control ‐ not measured · children (2 to < 18 years) in the general population Replacing salt with low‐sodium salt substitutes (LSSS) for cardiovascular health in adults, children and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ LSSS intervention vs regular salt Change in blood potassium (mmol/L) ‐ not measured · children (2 to < 18 years) in the general population Replacing salt with low‐sodium salt substitutes (LSSS) for cardiovascular health in adults, children and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ LSSS intervention vs regular salt Hyperkalaemia ‐ not measured · children (2 to < 18 years) in the general population Replacing salt with low‐sodium salt substitutes (LSSS) for cardiovascular health in adults, children and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ LSSS intervention vs regular salt Hypokalaemia ‐ not measured · children (2 to < 18 years) in the general population Replacing salt with low‐sodium salt substitutes (LSSS) for cardiovascular health in adults, children and… (2022) · Cochrane | no estimate extracted | NR | No studies |
JAK inhibitors plus standard of care vs standard of care (plus/minus placebo) Outcomes(Time frame of absolute effects) · hospitalised people with confirmed SARS‐CoV‐2 infection Janus kinase inhibitors for the treatment of COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Canakinumab vs standard care/placebo Clinical improvement D60 or above Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Canakinumab vs standard care/placebo WHO Clinical Progression Score of level 7 or above D60 or above Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Fluvoxamine plus standard care vs placebo plus standard care Symptom resolution · symptomatic people with COVID‐19 Fluvoxamine for the treatment of COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Fluvoxamine plus standard care vs placebo plus standard care Quality of life (at longest · symptomatic people with COVID‐19 Fluvoxamine for the treatment of COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Fluvoxamine plus standard care vs placebo plus standard care Suicide or suicide attempt (at longest · symptomatic people with COVID‐19 Fluvoxamine for the treatment of COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo Confirmed SARS‐CoV‐2 infection Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo Systemic reactogenicity events Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo Any adverse event Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo Serious adverse events Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo Local reactogenicity events Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Heterologous vaccination scheme vs homologous vaccination scheme Confirmed SARS‐CoV‐2 infection Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Heterologous vaccination scheme vs homologous vaccination scheme Confirmed symptomatic COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Heterologous vaccination scheme vs homologous vaccination scheme Severe or critical COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Heterologous vaccination scheme vs homologous vaccination scheme All‐cause mortality Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Booster vs placebo/no booster Confirmed SARS‐CoV‐2 infection Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Booster vs placebo/no booster Confirmed symptomatic COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Booster vs placebo/no booster Severe or critical COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Booster vs placebo/no booster Any adverse event Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |